Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02764697) enrolled 5 participants, all of whom received injections of H.P. Acthar Subcutaneous Gel. The trial was looking at two things in people with a condition affecting the middle layer of the eye (intermediate uveitis): whether a measure of eye cloudiness called "vitreous haze" improved over 12 weeks, and whether swelling at the centre of the back of the eye (macular oedema) improved. Of the 5 people who started, 2 completed the trial and 3 did not finish. The reported data shows that for the haze measurement — graded on a scale from 0 (clear) to 4 (very cloudy), where a lower score is better — the results listed across the reported time points were 3 participants, then 1 participant, then 1 participant meeting the improvement target (either reaching grade 0 or dropping by 2 steps on the scale). For the second measure, which looked at whether the central thickness of the back of the eye reduced to below a certain level (300 microns, as measured by a scanning tool called OCT), the reported data shows 0 participants met this target at one time point and 5 participants at another — however, the data as submitted does not clearly label which time points these figures belong to, so these numbers should be interpreted with caution. It is worth noting that this was a very small trial with only 5 participants, and the data as reported to ClinicalTrials.gov has some gaps in how the time points are labelled. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 4 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be able to understand and sign a consent form agreeing to take part in the study
- You must be 18 years old or older
- Both men and women can take part
- You must have had a negative tuberculosis (TB) test (either a skin test or a blood test) within the past 3 months
- You must have active inflammation in at least one eye
- You must have vision of at least 20/400 or better in at least one eye (this means being able to see at 20 feet what most people can see at 400 feet)
- You must have a history of glaucoma or be currently receiving treatment for glaucoma
- You must be willing and able to follow all study procedures and attend required visits
- If you are a woman who could become pregnant, you must not currently be pregnant or breastfeeding, must have a negative pregnancy test at the start of the study, and must agree to pregnancy testing throughout the study
Who may not be able to join:
- You have an active infection in your eye
- You have an active infection anywhere else in your body
- You have a documented condition that weakens or impairs your immune system
- You have another eye condition that makes it impossible to properly assess the inflammation in your eye (confirm with trial site)
- You have had eye surgery in the past 6 weeks
- You have any planned surgery (on your eyes or elsewhere in your body) during the study period
- You are currently pregnant or breastfeeding
- You have recently received a vaccine that contains a live or weakened form of a virus or bacteria
- You have a known sensitivity or allergy to proteins derived from pigs
- You have a medical history that means it would not be safe for you to receive the study drug, H.P. Acthar (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography; Number of Participants With Clinically Significant Improvement of Macular Edema
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.